MedWatch

Zealand-partner delays combination drug

Zealand pharma’s French partner Sanofi delays phase III studies with the combination drug Lantus/Lyxumia. Disappointing says CEO David Solomon about the development.

Foto: Sanofi/PR

Zealand Pharma will have to wait for results from a phase III study involving a new combination product that the Danish company had high hopes for. Technical issues with the specially developed Fix-Flex-pen have delayed the clinical studies, Zealand Pharma announced Thursday morning.

The combination product, which was heading into the final clinical trial phases, consists of Zealand Pharma’s diabetes drug Lyxumia and the world’s best-selling insulin product, Lantus, from Zealand’s French partner Sanofi.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier